[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100556913":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":30,"centralContacts":34,"locations":41,"responsibleParty":58,"collaborators":11,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":11,"eligibilityCriteria":67,"healthyVolunteers":63,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":11,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":83,"overallStatus":86,"whyStopped":11,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"RenJi Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Surufatinib + serplulimab + standard chemotherapy","EXPERIMENTAL",null,[13,14,15],"Drug: Surufatinib","Drug: Serplulimab","Drug: standard chemotherapy",[17,22,26],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":11},"DRUG","Surufatinib","250 mg, po, qd, q3w",[9],{"type":18,"name":23,"description":24,"armGroupLabels":25,"otherNames":11},"Serplulimab","200 mg, iv, d1, q3w",[9],{"type":18,"name":27,"description":28,"armGroupLabels":29,"otherNames":11},"standard chemotherapy","Decided by PI",[9],[31],{"name":32,"affiliation":5,"role":33},"Liwei Wang, Doctorate","PRINCIPAL_INVESTIGATOR",[35,39],{"name":32,"role":36,"phone":37,"phoneExt":11,"email":38},"CONTACT","+86 16621086648","lwwang2013@163.com",{"name":40,"role":36,"phone":37,"phoneExt":11,"email":38},"Liwei Wang",[42],{"facility":43,"status":11,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Renji hospital","Shanghai","Shanghai Municipality","200127","China","CN",{"type":50,"coordinates":51},"Point",[52,53],121.45806,31.22222,{"lat":53,"lon":52},[56],{"name":57,"role":36,"phone":37,"phoneExt":11,"email":38},"Liwei Wang, Dr",{"type":33,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"liwei wang","Director of department of oncology","100556913","phase-2-surufatinib-combined-with-serplulimab-and-standard-chemotherapy-as-first-line-treatment-in-advanced-solid-tumors-with-neuroendocrine-differentiation-100556913",false,"NCT06531291","Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation","Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation: A Single-arm, Multi-cohort, Open-label, Single-center, Prospective, Exploratory Clinical Study","Inclusion Criteria:\n\n* Histopathologically confirmed locally advanced or metastatic unresectable ESCC, BTC, PC or GC with an abnormal NED or NE phenotype (without neuroendocrine morphologic features and positive immunohistochemical expression of at least one neuroendocrine marker (CgA, Syn));\n* Have at least one measurable lesion according to RECIST v1.1;\n* ECOG performance status: 0-1;\n* No previous systemic therapy;\n* Urine protein\\\u003C ++ . If Urine protein ≥ ++ ,the amount of urine protein in 24 hours ≤1.0g;\n* Expected survival time \\> 3 months;\n\nExclusion Criteria:\n\n* Have uncontrolled hypertension, defined as systolic blood pressure \\>150 mmHg or diastolic blood pressure \\>90 mm Hg, while under anti-hypertension treatment;\n* With active bleeding or bleeding tendency;\n* Severe history of cardiovascular and cerebrovascular diseases;\n* Other malignancies diagnosed within the previous 5 years, except basal cell carcinoma or cervical carcinoma in situ after radical resection.","ALL","18 Years","75 Years",{"count":72,"type":73},80,"ESTIMATED","INTERVENTIONAL",[76],"PHASE2","Currently, there are no standard treatment and relevant exploration for solid tumors patients with NED. The study aims to explore the efficacy and safety of surufatinib combined with serplulimab and standard chemotherapy in the treatment ofadvanced solid tumors with NED, in order to provide a new treatment option for advanced solid tumors patients with NED.",[79,80,81,82],"ESCC","Biliary Tract Cancer","Gastric Cancer","Pancreas Cancer",[84,85],"surufatinib","Neuroendocrine Differentiation","NOT_YET_RECRUITING","2024-07-28",{"date":89,"type":90},"2024-07-31","ACTUAL",{"date":92,"type":73},"2024-08-10",{"date":94,"type":73},"2027-08-09",{"name":5,"class":6},1]